Announcements Trials
Browse Landscape

Phase

Phase 2 25Phase 3 5Phase NA 3Phase 4 3Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Neoplasms, Plasma Cell 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 155Carboplatin 147Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 119Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Clarithromycin × Clear all
NCT02542657 2024-09-19

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

University of California, Davis

Phase 1/2 Active not recruiting
30 enrolled
Plasma cell

Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡